Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status.
Nakashima K, Kodama H, Murakami H, Takahashi T, Kawakado K, Yanagawa T, Kitani K, Hottta T, Abe M, Hamai K, Tanimoto T, Ishikawa N, Tamura T, Kuyama S, Isobe T, Tsubata Y.
Nakashima K, et al. Among authors: takahashi t.
Respir Investig. 2024 Oct 3;62(6):1137-1141. doi: 10.1016/j.resinv.2024.09.010. Online ahead of print.
Respir Investig. 2024.
PMID: 39366122
Free article.